Trial · NCT03114995
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under Curve of Serial Cardiac Biomarkers | Group A (High Platelet Reactivity - Tirofiban) | Troponin I | 197.2 | Inter-Quartile Range 41.5 to 395.7 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C1 (High Platelet Reactivity - no Tirofiban) | Troponin I | 38.0 | Inter-Quartile Range 8.9 to 313.9 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C2 (Low Platelet Reactivity - no Tirofiban) | Troponin I | 121.4 | Inter-Quartile Range 43.7 to 481.8 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Group A (High Platelet Reactivity - Tirofiban) | creatine kinase-MB isoenzyme | 252.5 | Inter-Quartile Range 48.0 to 470.1 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C1 (High Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 92.7 | Inter-Quartile Range 39.1 to 402.1 | Hours*ng/ml |
| Area Under Curve of Serial Cardiac Biomarkers | Control C2 (Low Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 185.6 | Inter-Quartile Range 79.8 to 425.3 | Hours*ng/ml |
| Percentage of Participants With Periprocedural Myonecrosis | Group A (High Platelet Reactivity - Tirofiban) | Troponin I | 16 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C1 (High Platelet Reactivity - no Tirofiban) | Troponin I | 15 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C2 (Low Platelet Reactivity - no Tirofiban) | Troponin I | 26 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Group A (High Platelet Reactivity - Tirofiban) | creatine kinase-MB isoenzyme | 11 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C1 (High Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 10 | Participants | |
| Percentage of Participants With Periprocedural Myonecrosis | Control C2 (Low Platelet Reactivity - no Tirofiban) | creatine kinase-MB isoenzyme | 25 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03114995/results